PT Diastika Biotekindo Tbk
IIDX:CHEK104.00
IDR
+1.00
(+0.97%)
ISIN
ID1000211402
Return %
Stock
S&P 500
1Y
-44.68
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Franciscus Xaverius Raintjung
- Full Time Employees
- 106
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Jakarta Timur Indonesia
- IPO Date
- Jul 10, 2025
- Website
- diastika.co.id
- Similar Companies
- Business
- PT Diastika Biotekindo Tbk is an Indonesia-based healthcare technology and medical distribution company primarily engaged in the marketing, distribution, and servicing of in vitro diagnostic (IVD) reagents, clinical laboratory instruments, and biomedical supplies. Founded in 2007 and headquartered in Jakarta, Indonesia, the company operates as a specialized distributor connecting global medical device manufacturers with domestic healthcare facilities. Its comprehensive product and service portfolio encompasses automated clinical chemistry analyzers and reagent kits; hematology testing instruments, reagents, and automated cell counters; immunology and immunoturbidimetry diagnostic assays; molecular diagnostics, extraction systems, and polymerase chain reaction (PCR) platforms; point-of-care testing (POCT) devices, blood gas analyzers, and electrolyte meters; microbiology culture media and identification systems; urinalysis analyzers and test strips; and laboratory consumables, calibration materials, quality control serums, and disposable clinical supplies. Alongside equipment sales, the company provides technical and operational services comprising laboratory layout planning, instrument installation, preventative maintenance, routine calibration, repair services, and clinical operator training. PT Diastika Biotekindo Tbk serves a diversified client base consisting of public and private hospitals, commercial clinical laboratories, primary health centers (Puskesmas), blood transfusion centers, and academic research institutions across Indonesia, supported by regional distribution and cold-chain logistics hubs covering Java, Sumatra, Kalimantan, Sulawesi, and Eastern Indonesia. In recent developments, the company completed its initial public offering (IPO) on the Indonesia Stock Exchange under the ticker symbol CHEK to accelerate business expansion, fund working capital for inventory procurement, and enhance logistics infrastructure. The company has also broadened its strategic distribution partnerships with international diagnostic equipment manufacturers to introduce automated testing platforms, expanded its instrument placement and rental programs across domestic hospital networks to grow recurring reagent sales, and upgraded its cold-chain distribution facilities to strengthen delivery reliability across regional markets.